Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Professional Medical Journal-Quarterly [The]. 2002; 9 (4): 298-303
Dans Anglais | IMEMR | ID: emr-60647

Résumé

The present research, investigation aims demonstrating the. HER-2/neu oncoprotein over expression in endometrial adenocarcinoma and hyperplasia. This retrospective study was carried out in the department of pathology, Basic Medical Sciences lnstitute, JPMC, Karachi on formaline fixed paraffin embedded blocks of cases diagnosed as cystic hyperpIasia adenomatous hyperplasia and adenocarcinoma endomertium during 1996-2000. On the basis of, routine. light microscopic examination an initial diagnosis was made for immunohistochemical staining. LAB-SA [Labeled biotin streptavidine] method was preferred for its higher sensitivity arid less background staining. The cases of cystic hyperplasia subject to immunohistochemistry reveal 44.4% positively to HER-2/neu oncoprotein overexpression, the adenomatous hyperplasia revealed 55% expression to HER-2/neu oncoprotein. The over expression seen in all three grades of the adenocarcinoma being 65.5% [P=0.587]. It is concluded that the over expression to HER-2/neu oncoprotein is present in 44.4%, 55% and 65.5% in cystic hyperplasia, adenomatous hyperplasia and adenocarcinoma endometrium respectively. Statistically no significant correlation is seen in the HER-2/neu,oncoprotein and other prognostic factor e.g. histological subtype, grade, stage and age of the patient


Sujets)
Humains , Femelle , Hyperplasie endométriale/anatomopathologie , Protéines oncogènes , Récepteur ErbB-2 , Adénocarcinome , Immunohistochimie
SÉLECTION CITATIONS
Détails de la recherche